Michael J. Overman

Career Trajectory

Research Cluster Map

Direct collaborators. Node size = influence, colour = community, dashed = past collaboration.

• Abstract A027: Mode of presentation and symptoms at diagnosis of early- and late-onset colorectal cancer: a large retrospective AI-powered analysis

  Clinical Cancer Research · 2025-12-10

• ASO Visual Abstract: Clinicopathologic and Molecular Characteristics of High-Grade Appendiceal Mucinous Neoplasms

  Annals of Surgical Oncology · 2025-12-09

• Impact of <i>RAS</i> / <i>BRAF</i> V600E Mutations on the Tumor Immune Microenvironment in Mismatch Repair–Deficient/Microsatellite Instability Colorectal Cancers

  Clinical Cancer Research · 2025-11-13 · 1 citations

• Clinicopathologic and Molecular Characteristics of High-Grade Appendiceal Mucinous Neoplasms

  Annals of Surgical Oncology · 2025-11-12 · 2 citations

• Prognosis and treatment response stratification according to loss of proofreading (LOP) <i>POLE</i> variants

  Journal for ImmunoTherapy of Cancer · 2025-11-01 · 1 citations

• 1288 TME and molecular characteristics of <i>KRAS</i> ^Q61 mutated gastrointestinal malignancies and clinical outcomes

  Regular and Young Investigator Award Abstracts · 2025-11-01

• Abstract B003: Orally administered MOMA-341 as monotherapy or combination therapy in participants with advanced or metastatic solid tumors: Phase 1 study design

  Molecular Cancer Therapeutics · 2025-10-22 · 2 citations

• Abstract B049: Molecular Characteristics of <i>KRAS</i> Q61 Mutated Gastrointestinal Malignancies and Clinical Outcomes

  Molecular Cancer Therapeutics · 2025-10-22

• Performance characteristics of CMS' OP-35 quality measure: Sensitive but not specific.

  JCO Oncology Practice · 2025-10-01 · 1 citations

• Abstract B076: Clinical and Molecular Characteristics of <i>KRASQ61</i> Mutated Pancreatic Cancer and Other Gastrointestinal Malignancies

  Cancer Research · 2025-09-28

• 876eP Temporal and age-related patterns in mode of presentation for colorectal cancer: A large retrospective study enhanced by large language model (LLM) classification

  Annals of Oncology · 2025-09-01

• 986P Phase I study of NovoTTF-100L(P) in combination with chemotherapy in patients with predominant hepatic metastatic colorectal cancer

  Annals of Oncology · 2025-09-01

• 909eTiP Open-label phase II trial of AMB-05X for patients with ctDNA(+) colorectal cancer after curative-intent treatment

  Annals of Oncology · 2025-09-01

• 1529P Impact of severe immuno-related adverse events on survival in deficient mismatch repair/microsatellite instable-high gastro-intestinal (dMMR/MSI-H GI) cancers treated with immune checkpoint inhibitors (ICI)

  Annals of Oncology · 2025-09-01

• 802P Nous-209 immunotherapy with pembrolizumab for microsatellite instability high (MSI-H) metastatic colorectal cancer, refractory to anti-PD-1: Phase II trial results

  Annals of Oncology · 2025-09-01

• 732MO Circulating tumour DNA (ctDNA) clearance and correlation with outcome in the INTERCEPT colorectal cancer (CRC) study

  Annals of Oncology · 2025-09-01 · 4 citations

• Phase 1/2 trial of encorafenib, cetuximab, and nivolumab in microsatellite stable BRAFV600E metastatic colorectal cancer

  Cancer Cell · 2025-08-28 · 22 citations

• First-line PD-1 +/- CTLA-4 blockade in patients with deficient mismatch repair and/or microsatellite instability-high metastatic colorectal cancer

  The Oncologist · 2025-08-20 · 5 citations

• Prognostic impact of the BRAF V600E mutation in patients with MSI-high metastatic colorectal cancer treated with immune checkpoint inhibitors

  European Journal of Cancer · 2025-07-15 · 8 citations

• 243P Clinical performance of Signatera genome assay in a sub-cohort of locally advanced rectal cancer (LARC) patients (pts) in the MD Anderson INTERCEPT program

  Annals of Oncology · 2025-07-01